SPIKE$: A six-step protocol for delivering bad news about the cost of medical care

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4200-4204

  McFarlane, Joshua ^a   Riggins, Jerry ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; ERLOTINIB; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; LETROZOLE; MITOMYCIN; PACLITAXEL; PAMIDRONIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; HEALTH CARE COST; LUNG NON SMALL CELL CANCER; MEDICAL CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REIMBURSEMENT; SHORT SURVEY; SOCIOECONOMICS;

ANTINEOPLASTIC AGENTS; COMMUNICATION; ECONOMICS, MEDICAL; HUMANS; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAL ONCOLOGY; NEOPLASMS; PERCEPTION; PHYSICIAN-PATIENT RELATIONS; TRUTH DISCLOSURE;

EID: 51649104340     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.6208     Document Type: Short Survey

References (31)

1. Baile WF, Buckman R, Lenzi R, et al: SPIKES: A six-step protocol for delivering bad news - Application to the patient with cancer. Oncologist 5:302-311, 2000
2. Bodenheimer T: High and rising health care costs: Part 1 - Seeking an explanation. Ann Intern Med 142:847-854, 2005
3. Meropol NJ, Schulman KA: Cost of cancer care: Issues and implications. J Clin Oncol 25:180-186, 2007
4. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
5. Shepherd FA, Rodrigues Pereira J, et al: Erlotinib in previously treated non-small-cell lung cancer (National Cancer Institute of Canada Clinical Trials Group). N Engl J Med 353:123-132, 2005
6. Arozullah AM, Calhoun EA, Wolf M, et al: The financial burden of cancer: Estimates from a study of insured women with breast cancer. J Support Oncol 2:271-278, 2004 May-Jun
7. Garber AM, McClellan MB: Satisfaction guaranteed: "Payment by results" for biologic agents. N Engl J Med 357:1575-1577, 2007
8. Benner SE, Fetting JH, Brenner MH: A stopping rule for standard chemotherapy for metastatic breast cancer: Lessons from a survey of Maryland medical oncologists. Cancer Invest 12:451-455, 1994
9. Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490-3496, 2006
10. Grunfeld EA, Maher EJ, Browne S, et al: Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol 24:1090-1098, 2006
11. Chochinov HM, Wilson KG, Enns M, et al: "Are you depressed?" Screening for depression in the terminally ill. Am J Psychiatry 154:674-676, 1997
12. Earle CC, Neville BA, Landrum MB, et al: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315-321, 2004
13. Emanuel EJ, Young-Xu Y, Levinsky NG, et al: Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 138:639-643, 2003
14. Smith TJ: Tell it like it is. J Clin Oncol 18:3441-3445, 2000
15. Bruera E, Sweeney C, Willey J, et al: Breast cancer patient perception of the helpfulness of a prompt sheet versus a general information sheet during outpatient consultation: A randomized, controlled trial. J Pain Symptom Manage 25:412-419, 2003
16. Brown RF, Butow PN, Dunn SM, et al: Promoting patient participation and shortening cancer consultations: A randomised trial. Br J Cancer 85:1273-1279, 2001
17. Glynne-Jones R, Ostler P, Lumley-Graybow S, et al: Can I look at my list? An evaluation of a 'prompt sheet' within an oncology outpatient clinic. Clin Oncol (R Coll Radiol) 18:395-400, 2006
18. Teno JM: Advance directives: Time to move on. Ann Intern Med 141:159-160, 2004
19. The AM, Hak T, Koeter G, et al: Collusion in doctor-patient communication about imminent death: An ethnographic study. West J Med 174:247-253, 2001
20. Koedoot CG, Oort FJ, de Haan RJ, et al: The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: Palliative chemotherapy and watchful-waiting. Eur J Cancer 40:225-235, 2004
21. Gelband H, Foley KM (eds): Improving Palliative Care for Cancer. Washington DC, National Cancer Policy Board, National Academy of Science. 2001
22. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
23. Lamont EB, Siegler M: Paradoxes in cancer patients' advance care planning. J Palliat Med 3:27-35, 2000
24. Miller TE, Horowitz ER: Disclosing doctors' incentives: Will consumers understand and value the information? Health Aff (Millwood) 19:149-155, 2000
25. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 25:437-443, 2006
26. Hagerty RG, Butow PN, Ellis PM, et al: Communicating with realism and hope: Incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 23:1278-1288, 2005
27. Kirk P, Kirk I, Kristjanson LJ: What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study. BMJ 328:1343, 2004
28. Matsuyama RK, Grange C, Lyckholm LJ, et al: Cultural perceptions in cancer care among African-American and Caucasian patients. J Natl Med Assoc 99:1113-1118, 2007
29. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: When is chemotherapy "too much"? JAMA 299:2667-2678, 2008
30. Cherlin E, Fried T, Prigerson HG, et al: Communication between physicians and family caregivers about care at the end of life: When do discussions occur and what is said? J Palliat Med 8:1176-1185, 2005
31. Bodurtha JN: What's this going to cost, Doctor? Acad Med 71:937-938, 1996